Russian Lab Achieves ISO Accreditation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Russian Lab Achieves ISO Accreditation



The Rostov-on-Don Medicines Quality Control Laboratory of the Federal Service on Surveillance in Healthcare (Roszdravnadzor) has attained ISO/IEC 17025:2005 accreditation for testing and calibration laboratories. The facility is the first official medicines control laboratory in Russia to have achieved internationally recognized ISO accreditation, according to a press release from the U.S. Pharmacopeial (USP) Convention.

The accreditation was awarded by ACLASS, an accrediting body based in Washington, D.C., for seven key analytical tests: high-performance liquid chromatography, dissolution, ultra-violet visible spectroscopy, thin-layer chromatography, Karl Fischer titration, pH, and limulus amebocyte lysate.

The accreditation certifies that the Rostov-on-Don laboratory is providing valid and trustworthy data to Roszdravnadzor, the Russian drug-monitoring agency, helping to ensure the distribution of good quality medicines. The USP, provided technical assistance to Roszdravnadzor through its Promoting the Quality of Medicines (PQM) program. Assistance included conducting an assessment of the Rostov-on-Don laboratory’s quality management system against ISO/IEC standards; providing ongoing monitoring of the laboratory’s progress toward accreditation; and hosting Roszdravnadzor staff at its US headquarters to observe how USP’s quality management system complies with ISO standards. This support occurred in several stages between September 2011 and October 2012.

ISO/IEC 17025:2005 accreditation positions Rostov-on-Don as an international reference for labs working on quality control of pharmaceutical products. It extends the lab’s reach in supporting public health across Russia and the wider region.

 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here